First field trial of a transmissible recombinant vaccine against myxomatosis and rabbit hemorrhagic disease

Torres, Juan María; Sánchez, Carmen; Ramírez, Miguel Ángel; Morales, Mónica; Bárcena, Juan; Ferrer, Joan Genescà; Espuña, E.; Pagès-Manté, Albert; Sánchez‐Vizcaíno, José Manuel

doi:10.1016/s0264-410x(01)00184-0

Cited by 44 publications

(38 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, no nucleotide changes had accumulated during the selection of the recombinant virus. This result was in agreement with our previous observations, indicating that both viruses exhibited indistinguishable biological features (6,7,56,57).…”

supporting

confidence: 94%

“…Interestingly, M135R is one of the seven MV genes absent in SFV (13,61). It is noteworthy that the clinical symptoms induced by vMyx135KO (10) closely resemble those previously described for 6918 or the derived recombinant virus 6918VP60-T2 (6,7,56,57), strongly suggesting that disruption of M135R is an important determinant of 6918 attenuation.…”

supporting

confidence: 68%

“…It has been used for the development of a "transmissible vaccine" intended to protect wild-rabbit populations against both myxomatosis and rabbit hemorrhagic disease virus (RHDV) in Spain, where the European rabbit plays a key role in the Mediterranean ecosystems (18). For this purpose, a recombinant virus, 6918VP60-T2, was constructed by inserting the capsid gene of RHDV into the genome of strain 6918 (4,6,7,56,57). The genomes of 6918 and 6918VP60-T2 have been sequenced.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Genome Comparison of a Nonpathogenic Myxoma Virus Field Strain with Its Ancestor, the Virulent Lausanne Strain

Morales¹,

Ramírez²,

Cano³

et al. 2009

J Virol

View full text Add to dashboard Cite

One of the best-studied examples of host-virus coevolution is the release of myxoma virus (MV) for biological control of European rabbits in Australia and Europe. To investigate the genetic basis of MV adaptation to its new host, we sequenced the genome of 6918, an attenuated Spanish field strain, and compared it with that of Lausanne, the strain originally released in Europe in 1952. Although isolated 43 years apart, the genomes were highly conserved (99.95% identical). Only 32 of the 159 MV predicted proteins revealed amino acid changes. Four genes (M009L, M036L, M135R, and M148R) in 6918 were disrupted by frameshift mutations.

show abstract

supporting

confidence: 94%

supporting

confidence: 68%

mentioning

confidence: 99%

See 1 more Smart Citation

Genome Comparison of a Nonpathogenic Myxoma Virus Field Strain with Its Ancestor, the Virulent Lausanne Strain

Morales¹,

Ramírez²,

Cano³

et al. 2009

J Virol

View full text Add to dashboard Cite

show abstract

“…It would also be prudent for countries where rabbits are regarded as pests and where MV and/or RHDV are present to attempt to protect the utility of these BCAs by minimising the risk of entry of the disseminating GMO developed in Spain (but not yet released from quarantine) to immunise rabbits against MV and RHDV (Torres et al 2001;Angulo and Bárcena 2007). Although this GMO appears to possess a limited capacity for horizontal transmission, this might not remain the case in the wild if genetic recombination introduces the transgenes into a more transmissible strain of MV.…”

Section: Discussionmentioning

confidence: 99%

The future biological control of pest populations of European rabbits, Oryctolagus cuniculus

2008

View full text Add to dashboard Cite

Abstract. European rabbits are exotic pests in Australia, New Zealand, parts of South America and Europe, and on many islands. Their abundance, and the damage they cause, might be reduced by the release of naturally occurring or genetically modified organisms (GMOs) that act as biological control agents (BCAs). Some promising pathogens and parasites of European rabbits and other lagomorphs are discussed, with special reference to those absent from Australia as an example of the range of necessary considerations in any given case. The possibility of introducing these already-known BCAs into areas where rabbits are pests warrants further investigation. The most cost-effective method for finding potentially useful but as-yet undiscovered BCAs would be to maintain a global watch on new diseases and pathologies in domestic rabbits. The absence of wild European rabbits from climatically suitable parts of North and South America and southern Africa may indicate the presence there of useful BCAs, although other explanations for their absence are possible. Until the non-target risks of deploying disseminating GMOs to control rabbits have been satisfactorily minimised, efforts to introduce BCAs into exotic rabbit populations should focus on naturally occurring organisms. The development of safe disseminating GMOs remains an important long-term goal, with the possible use of homing endonuclease genes warranting further investigation.

show abstract

“…Both of these vaccines have limitations, Shope fibroma virus induces relatively short-term protection against myxomatosis [9,14,18] and the attenuated SG33 strain of myxoma virus has been associated with immunosuppression in young rabbits [7]. Attenuated live virus vaccines have also been investigated to protect wild rabbits in Europe [2,27,30].…”

Section: Introductionmentioning

confidence: 99%

Construction and testing of a novel host-range defective myxoma virus vaccine with the M063 gene inactivated that is non-permissive for replication in rabbit cells

et al. 2008

View full text Add to dashboard Cite

-Deletion of the M063 gene from myxoma virus produces a virus that is unable to replicate in rabbit cells in vitro or in live rabbits but can be propagated in non-rabbit cell lines. A targeted M063 deletion mutant was constructed in the attenuated Uriarra strain of myxoma virus and the ability of this virus to act as a safe, non-transmissible vaccine against myxomatosis was tested in outbred laboratory rabbits. Immunization with the M063 deletion vaccine provided good short-term protection against lethal challenge with virulent myxoma virus. Long-term protection was similar to reported results with heterologous live virus, with some rabbits protected but others succumbing to challenge. Replication-deficient poxvirus vaccines, like the Modified Vaccinia Virus Ankara (MVA) in man and the myxoma virus vaccine described here in rabbits, are very attractive from a safety perspective. Seasonal boosting would be predicted to provide long-term protection. Targeted host-range gene deletions could have potential for rapid development of poxvirus vaccines in general. myxomatosis / vaccine / host-range / poxvirus / rabbits

show abstract

First field trial of a transmissible recombinant vaccine against myxomatosis and rabbit hemorrhagic disease

Cited by 44 publications

References 19 publications

Genome Comparison of a Nonpathogenic Myxoma Virus Field Strain with Its Ancestor, the Virulent Lausanne Strain

Genome Comparison of a Nonpathogenic Myxoma Virus Field Strain with Its Ancestor, the Virulent Lausanne Strain

The future biological control of pest populations of European rabbits, Oryctolagus cuniculus

Construction and testing of a novel host-range defective myxoma virus vaccine with the M063 gene inactivated that is non-permissive for replication in rabbit cells

Contact Info

Product

Resources

About